Ovid Therapeutics
OVID
71 hedge funds and large institutions have $11.9M invested in Ovid Therapeutics in 2025 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 27 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 82 → 71 (-11)
14.7% less ownership
Funds ownership: 65.28% → 50.58% (-15%)
18% less capital invested
Capital invested by funds: $14.5M → $11.9M (-$2.61M)
27% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 22
37% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$323K |
| 2 |
Millennium Management
New York
|
+$317K |
| 3 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$151K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$91K |
| 5 |
Goldman Sachs
New York
|
+$54K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$1.46M |
| 2 |
BlackRock
New York
|
-$750K |
| 3 |
JP Morgan Chase
New York
|
-$363K |
| 4 |
MAP
Madison Avenue Partners
New York
|
-$348K |
| 5 |
State Street
Boston,
Massachusetts
|
-$345K |
OVID Hedge Fund Activity: Q2 2025 in Review
71 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2025, worth a combined $11.9M — down 18% from $14.5M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of OVID and 17 opened new positions — a net loss of 10 holders — while 22 trimmed existing stakes and 16 added.
The largest buyer was Renaissance Technologies, adding an estimated $323K. The largest seller was Rubric Capital Management (New York), cutting an estimated $1.46M.
- 71 institutional investors held Ovid Therapeutics (OVID) as of Q2 2025, down from 82 in Q1 2025.
- Funds reported $11.9M of Ovid Therapeutics stock for Q2 2025, down 18% quarter-over-quarter.
- 17 funds opened new Ovid Therapeutics positions in Q2 2025 and 27 closed out, a net change of -10 holders.
- The largest Ovid Therapeutics buyer in Q2 2025 was Renaissance Technologies, an estimated $323K added.
- The largest Ovid Therapeutics seller in Q2 2025 was Rubric Capital Management (New York), an estimated $1.46M sold.
Based on aggregated 13F filings for Q2 2025.